Evidence map›Paper›PMID 36495048›Full record

ArticleThoracic cancer2023

Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.

Kana Fujimoto, Satomi Watanabe, Yuto Yasuda, Emi Date, Yasuhiro Kawabata, Hiroaki Kanemura, Takayuki Takahama, Kimio Yonesaka, Norishige Iizuka, Ken-Ichi Takahashi and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kana FujimotoDepartment of Respiratory Medicine, Kishiwada City Hospital, Kishiwada, Japan.
Satomi WatanabeDepartment of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.ORCID 0000-0002-0487-8721
Yuto YasudaDepartment of Respiratory Medicine, Kishiwada City Hospital, Kishiwada, Japan.
Emi DateDepartment of Pathology, Kishiwada City Hospital, Kishiwada, Japan.
Yasuhiro KawabataDepartment of Neurosurgery, Kishiwada City Hospital, Kishiwada, Japan.
Hiroaki KanemuraDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Takayuki TakahamaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Kimio YonesakaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Norishige IizukaDepartment of Pathology, Kishiwada City Hospital, Kishiwada, Japan.
Ken-Ichi TakahashiDepartment of Respiratory Medicine, Kishiwada City Hospital, Kishiwada, Japan.
Osamu KawakamiDepartment of Neurosurgery, Kishiwada City Hospital, Kishiwada, Japan.
Tomohiro OzakiDepartment of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Kishiwada City Hospital · JPKindai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade fetal lung adenocarcinoma (H-FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56-year-old man with stage IV H-FLAC who was successfully treated with carboplatin plus nab-paclitaxel in combination with atezolizumab. In addition, the tumor was found to be positive for amplification of the human epidermal growth factor receptor 2 gene.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinHumansLungMaleMiddle AgedAntibodies, Monoclonal, HumanizedatezolizumabCarboplatinatezolizumabcase reporthigh-grade fetal lung adenocarcinoma (H-FLAC)human epidermal growth factor receptor 2 (HER2, ERBB2)immunotherapy

Identifiers

PMID36495048
PMCPMC9834689
OpenAlexW4311021221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.